( May 6, 2025, 12:33 PM EDT) -- AMARILLO, Texas — The U.S. Food and Drug Administration urges a Texas federal court to dismiss an amended complaint filed by Missouri, Kansas and Idaho in a case originated by a group of antiabortion advocates challenging the FDA’s approval of the abortion drug mifepristone, a case that eventually reached the U.S. Supreme Court, which found that the original plaintiffs lacked standing, with the Trump administration now taking the same position as its predecessor and arguing in a reply brief filed May 5 that the intervening states cannot satisfy venue requirements to continue in the Texas court....